دورية أكاديمية
أعرض في EDS

Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
المؤلفون: Faleck DM; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: faleckd@mskcc.org., Shmidt E; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota., Huang R; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York., Katta LG; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida., Narula N; Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Pinotti R; Levy Library, Icahn School of Medicine at Mount Sinai, New York, New York., Suarez-Farinas M; Department of Population Health Science and Policy, Department of Genetics and Genomics Science, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York., Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
المصدر: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2021 Feb; Vol. 19 (2), pp. 238-245.e4. Date of Electronic Publication: 2020 Jun 20.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-7714 (Electronic) Linking ISSN: 15423565 NLM ISO Abbreviation: Clin Gastroenterol Hepatol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : W.B. Saunders for the American Gastroenterological Association, 2003-
مواضيع طبية MeSH: Crohn Disease*/drug therapy , Tumor Necrosis Factor Inhibitors*, Humans ; Infliximab ; Remission Induction ; Steroids ; Tumor Necrosis Factor-alpha
مستخلص: Background & Aims: It is not clear whether concomitant therapy with corticosteroids and anti-tumor necrosis factor (TNF) agents is more effective at inducing remission in patients with Crohn's disease (CD) than anti-TNF monotherapy. We aimed to determine whether patients with active CD receiving corticosteroids during induction therapy with anti-TNF agents had higher rates of clinical improvement than patients not receiving corticosteroids during induction therapy.
Methods: We systematically searched the MEDLINE, Embase, and CENTRAL databases, through January 20, 2016, for randomized trials of anti-TNF agents approved for treatment of CD and identified 14 trials (5 of adalimumab, 5 of certolizumab, and 4 of infliximab). We conducted a pooled meta-analysis of individual patient and aggregated data from these trials. We compared data from participants who continued oral corticosteroids during induction with anti-TNF therapy to those treated with anti-TNF agents alone. The endpoints were clinical remission (CD activity index [CDAI] scores <150) and clinical response (a decrease in CDAI of 100 points) at the end of induction (weeks 4-14 of treatment).
Results: We included 4354 patients who received induction therapy with anti-TNF agents, including 1653 [38.0%] who were receiving corticosteroids. The combination of corticosteroids and an anti-TNF agent induced clinical remission in 32.0% of patients, whereas anti-TNF monotherapy induced clinical remission in 35.5% of patients (odds ratio [OR], 0.93; 95% CI, 0.74-1.17). The combination of corticosteroids and an anti-TNF agent induced a clinical response in 42.7% of patients, whereas anti-TNF monotherapy induced a clinical response in 46.8% (OR 0.84; 95% CI, 0.73-0.96). These findings did not change with adjustment for baseline CDAI scores and concurrent use of immunomodulators.
Conclusions: Based on a meta-analysis of data from randomized trials of anti-TNF therapies in patients with active CD, patients receiving corticosteroids during induction therapy with anti-TNF agents did not have higher rates of clinical improvement compared with patients not receiving corticosteroids during induction therapy. Given these findings and the risks of corticosteroid use, clinicians should consider early weaning of corticosteroids during induction therapy with anti-TNF agents for patients with corticosteroid-refractory CD.
(Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.)
التعليقات: Comment in: Clin Gastroenterol Hepatol. 2022 Feb;20(2):468-469. (PMID: 33727165)
Comment in: Clin Gastroenterol Hepatol. 2022 Feb;20(2):469. (PMID: 33839279)
References: Am J Gastroenterol. 2012 Sep;107(9):1409-22. (PMID: 22890223)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
N Engl J Med. 2007 Jul 19;357(3):239-50. (PMID: 17634459)
Ann Intern Med. 2007 Nov 20;147(10):699-702. (PMID: 18025446)
Clin Gastroenterol Hepatol. 2019 Apr;17(5):818-823. (PMID: 30196164)
BMJ. 2017 Jun 19;357:j2505. (PMID: 28630047)
Inflamm Bowel Dis. 2014 Apr;20(4):622-30. (PMID: 24583478)
Lancet. 2002 May 4;359(9317):1541-9. (PMID: 12047962)
Ann Intern Med. 2007 Jun 19;146(12):829-38. (PMID: 17470824)
Gastroenterology. 2005 Sep;129(3):807-18. (PMID: 16143120)
Gastroenterology. 2012 May;142(5):1102-1111.e2. (PMID: 22326435)
N Engl J Med. 2010 Apr 15;362(15):1383-95. (PMID: 20393175)
N Engl J Med. 1999 May 6;340(18):1398-405. (PMID: 10228190)
Am J Gastroenterol. 2002 Apr;97(4):803-23. (PMID: 12003413)
Gastroenterology. 1979 Oct;77(4 Pt 2):847-69. (PMID: 38176)
N Engl J Med. 2007 Jul 19;357(3):228-38. (PMID: 17634458)
Gastroenterology. 2007 Jan;132(1):52-65. (PMID: 17241859)
JAMA. 2011 Dec 7;306(21):2331-9. (PMID: 22056398)
Mayo Clin Proc. 2008 Feb;83(2):181-94. (PMID: 18241628)
Gastroenterology. 2014 Mar;146(3):681-688.e1. (PMID: 24269926)
Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. (PMID: 20451663)
Am J Gastroenterol. 2011 Apr;106(4):590-9; quiz 600. (PMID: 21407179)
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. (PMID: 16472588)
PLoS One. 2016 Jun 23;11(6):e0158017. (PMID: 27336296)
J Crohns Colitis. 2012 Mar;6(2):160-73. (PMID: 22325170)
Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. (PMID: 21642014)
Lancet. 2017 Apr 29;389(10080):1741-1755. (PMID: 27914655)
Aliment Pharmacol Ther. 2002 Jan;16(1):51-60. (PMID: 11856078)
Ann Intern Med. 2019 Jan 15;170(2):99-107. (PMID: 30534946)
Am J Gastroenterol. 2018 Mar;113(3):405-417. (PMID: 29336432)
Gastroenterology. 2006 Apr;130(4):1054-61. (PMID: 16618399)
N Engl J Med. 2004 Feb 26;350(9):876-85. (PMID: 14985485)
Am J Gastroenterol. 2016 Dec;111(12):1806-1815. (PMID: 27670599)
BMJ. 2011 Jul 22;343:d4002. (PMID: 21784880)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Biologic; IBD; Inflammatory Bowel Diseases; RCT
المشرفين على المادة: 0 (Steroids)
0 (Tumor Necrosis Factor Inhibitors)
0 (Tumor Necrosis Factor-alpha)
B72HH48FLU (Infliximab)
تواريخ الأحداث: Date Created: 20200623 Date Completed: 20210818 Latest Revision: 20220314
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8364422
DOI: 10.1016/j.cgh.2020.06.036
PMID: 32569749
قاعدة البيانات: MEDLINE
الوصف
تدمد:1542-7714
DOI:10.1016/j.cgh.2020.06.036